H eart failure afflicts >5 million Americans, 1 with 700 000 people newly diagnosed each year. 2 In 2013, heart failure cost our healthcare system >$32 billion and is expected to double by 2030. 2 A considerable proportion of hospitalized patients with heart failure have inotrope-dependent stage D heart failure [3] [4] [5] and experience a 1-year survival rate of only 25%. [6] [7] [8] The nationwide cost of index hospitalizations alone for orthotopic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation approached $1 billion in 2009. 9 
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OHT is considered the definitive therapy for patients with inotrope-dependent stage D heart failure, with 1-year survival exceeding 85%. 10, 11 Median survival for all OHT recipients is currently 10 years, increasing to 13 years conditional on surviving the first year. 10 More than 3500 people are currently listed for OHT, with a median wait-list time of 5 to 6 months, 12 although only 2200 OHT operations are performed annually in the United States, in part attributable to limited donor availability. 10, 13 Randomized clinical trials involving patients with stage D heart failure have demonstrated improvements in survival among transplant-ineligible patients undergoing LVAD implantation as destination therapy (DT). The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial showed a 48% reduction in risk of death in LVAD patients when compared with patients receiving inotrope-dependent medical therapy (IDMT). 6 Heartmate-II investigators subsequently showed that patients implanted with continuous-flow LVADs achieved a 54% reduction in risk of death when compared with patients implanted with earlier LVADs used in the REMATCH trial.
of an LVAD does not seem to impact survival after OHT, although this is currently under debate. 17, 18 Although ≈1800 LVADs were implanted in the United States in 2012-more than double the number implanted in 2008. Although these predictions are challenging to establish, it has been estimated that far more patients might be eligible for LVAD or OHT in the United States alone. 15, 19 Given the substantial costs of both procedures, 9 the economic impact of such strategies deserves consideration. In this analysis, we evaluated the health benefits, survival, costs, and comparative cost-effectiveness of treatment strategies for patients with inotrope-dependent stage D heart failure.
Methods

Study Design
We developed a novel decision-analytic model ( Figure 1 ) to estimate survival and costs among patients with inotrope-dependent stage D heart failure under different treatment strategies. Among transplant-ineligible patients, we compared IDMT with DT-LVAD. For transplant-eligible patients, we evaluated IDMT, OHT, BTT-LVAD, and DT-LVAD. Although these patients would likely receive a heart transplant once a suitable organ becomes available, we included DT-LVAD as a hypothetical scenario to assess whether conditions exist where it may be preferable to receive DT-LVAD in lieu of BTT or OHT. In addition, the DT-LVAD strategy characterizes patients who start as BTT-LVAD but become ineligible for OHT and thereby convert to a DT-LVAD platform by default. Sensitivity analyses on parameters were performed to test model assumptions. Additional details are provided in the Appendix in the Data Supplement. The study was approved by the Human Investigations Committee of the Human Research Protection Program at Yale University.
A health state-transition model with 1-month cycle lengths was created to simulate a cohort of 20 000 hypothetical patients. Each month, patients transition between health states based on the risk of developing condition-specific complications or dying, with transition probabilities were derived from survival rates reported in the literature (Appendix Table I in the Data Supplement). Probability values were modeled as time varying, where appropriate, to more accurately reflect clinical course. Age-related mortality rates were estimated from Centers for Disease Control life tables, 20 with a base-case initial patient age of 50 years (Appendix Table II in the Data Supplement). All analyses were conducted using a lifetime horizon. The model was implemented in TreeAge Pro 2013 Software.
Survival Rates
We calibrated the model to published survival rates for ≤4 years follow-up in LVAD patients and 7 years for transplant patients Table 1 ). Beyond these time horizons, we extrapolated the appropriate mortality rates to project future survival; however, the model may be updated to reflect newer estimates as data become available.
Contemporary survival rates for LVAD patients were obtained from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), which enrolled 6885 LVAD patients between 2006 and 2012. 15 LVAD survival at 6, 12, and 24 months was 88%, 82%, and 74%, respectively. We assumed a higher mortality rate in the first month postimplantation and increased rates of serious complications which contribute to higher mortality for the first 12 months postimplantation. Beyond 12 months, we assumed a constant monthly mortality hazard rate based on a similar observation in INTERMACS from 12 to 48 months. 15 Our model closely matches INTERMACS data for patients with continuous-flow LVADs in the current era (Appendix Figure I in the Data Supplement). 15, 29 We also assumed 5% lower survival at 1 year for DT patients ineligible for OHT. 15 OHT survival was obtained from the International Society of Heart and Lung Transplantation (ISHLT), where post-transplant survival rates for years 1 through 7 were 86%, 82%, 79%, 76%, 73%, 69%, and 66%, respectively. 10 We calibrated transition probabilities to closely match ISHLT data (Appendix Figure II in the Data Supplement); we assumed a higher mortality rate for the first 12 months post-transplantation, but then a constant monthly mortality rate thereafter. Similar post-transplant mortality rates were used for patients who received IDMT or LVAD pretransplantation. 11, [16] [17] [18] The median wait-list time to receive a heart in the United States was 5.6 months based on the Scientific Registry of Transplant Recipients (SRTR). 12 In our model, we randomly generated a different wait-list time for each patient, such that the median wait time is 5.6 months. Under a constant hazard rate of an organ becoming available, this implies that 77% of patients receive a heart within 1 year. Estimates of survival among patients receiving IDMT vary widely, in part because of differences in baseline patient characteristics. The REMATCH trial demonstrated survival rates of 23% at 1 year and 8% at 2 years among OHT-ineligible patients, which formed the basis for our survival assumptions in this population. 6, 7 Survival estimates for OHT-eligible patients on IDMT were based on an analysis of United Network for Organ Sharing status 1A and 1B patients who did not receive an LVAD while awaiting OHT. Survival rates of 63%, 40%, and 16% at 6 months, 1 year, and 2 years, respectively, were assumed in our analysis of OHT-eligible IDMT patients. 21 In addition to estimating survival curves based on our simulation, we calculated the mean life expectancy associated with each treatment modality. We simulated each patient's health state transitions according to the mortality and complication rates until death. We then averaged across all patients to compute the mean life expectancy.
Complication Rates
Our model captured the development of specific clinical complications ( Figure 1 ) and accounted for the associated costs and quality-of-life decrements. After LVAD implantation, common complications include stroke, gastrointestinal bleeding, driveline infection, or pump failure requiring device replacement. 40 Among heart transplant recipients, organ rejection, cardiac allograft vasculopathy, renal dysfunction, and malignancy are possible complications. BTT-LVAD patients may experience complications resulting from either LVAD or OHT. All complication rates were validated against published estimates (Appendix Table III in the Data Supplement).
Quality of Life and Costs
Outcomes estimated for each strategy were average life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) relative to the next-best strategy in terms of cost per life-year gained or QALY gained. We adhered to recommendations for cost-effectiveness studies by using a societal perspective and discounting both costs and QALYs at a 3% annual rate. 41 Quality-of-life estimates were obtained from literature review (Table 1) . Each health state was associated with a quality-of-life value ranging from 0 to 1, where 0 represents death and 1 represents ideal health. QALYs were computed by aggregating the total time spent in each health state and applying the appropriate utility weight.
The costs of each treatment intervention, associated complications, and follow-up health care were estimated (Table 1 ). All costs were updated to 2012 US dollars using the medical care component of the consumer price index. 42 Direct medical costs associated with the index hospitalization for LVAD implantation and OHT were based on the Heartmate-II DT trial 24 and the Nationwide Inpatient Sample. 
Results
Base-Case Analysis
Based on a simulation of 20 000 patients with inotrope-dependent stage D heart failure aged 50 years (Figure 2 ), average life expectancy for OHT-eligible patients on IDMT was 1.1 years, with a 1-year survival rate of 40%, consistent with published estimates. 43 Similar patients who immediately receive OHT live for an additional 13.8 years on average, with a 5-year survival rate of 74%. Our model results are similar to post-transplantation survival estimates reported by ISHLT. 10, 22 However, because patients typically face a waiting period before a heart becomes available, we calculated life expectancy while accounting for this wait-list time. Given a median OHT wait-list time of 5.6 months, life expectancy is 8.5 years, with a 5-year survival rate of 44%, assuming patients received IDMT while awaiting OHT. Patients with similar transplant wait-list times who instead receive BTT-LVAD live an additional 12.3 years on average, slightly less than patients who are immediately transplanted (13.8 years) because of LVADassociated complications and surgical mortality risk (Table 2) .
Among patients who are OHT ineligible, the average life expectancy with IDMT was 9.4 months with a 1-year survival of 26%, consistent with prior reports. 6 Alternatively, from extrapolation of recent constant hazard rates beyond the first year, DT-LVAD quintuples life expectancy to 4.4 years in OHT-ineligible patients, generating 1-year and 2-year survival rates of 78% and 62%, respectively, consistent with reports in the literature. 
Cost-Effectiveness Analysis
Under the base-case scenario, OHT costs ≈$97 000 per QALY gained or $54 000 per life-year gained relative to IDMT in OHT-eligible patients (Figure 3) . If a patient from this cohort receives BTT-LVAD, the ICER exceeds $226 000 per QALY gained relative to OHT, primarily attributable to the substantial inpatient hospital costs associated with both procedures. In the hypothetical scenario where an OHT-eligible patient underwent LVAD implantation with the intention of later undergoing OHT, but for whatever reason converted to DT-LVAD, this strategy would cost $175 000 per QALY gained but would confer fewer QALYs than OHT or BTT-LVAD. In OHT-ineligible patients, DT-LVAD carries an ICER of $202 000 per QALY gained or $132 000 per life-year gained, compared with medical therapy.
Sensitivity Analyses
Age Our base-case simulation considered 50-year-old patients.
As patients age, all cohorts experience a decrease in life expectancy driven by age-related mortality (Figure 4) , resulting in worsening cost-effectiveness. We projected 75-year-old LVAD patients' survival rates of 78% (1 year), 65% (2 years), and 52% (3 years). INTERMACS reports survival rates of 75%, 63%, and 54% for patients aged ≥70 years. 44 Among 75-year-old heart transplant recipients, we projected post-transplant survival rates of 86%, 80%, 73%, 67%, and 60% at years 1 through 5, respectively, compared with 80%, 76%, 72%, 67%, and 66% reported by ISHLT for patients aged ≥70 years. 10 Modest survival rate differences may arise because both INTERMACS and ISHLT pool survival data for all patients aged >70 years.
In OHT-eligible patients, OHT costs <$100 000 per QALY gained relative to IDMT in patients aged <63 years, whereas BTT-LVAD exceeds $200 000 per QALY gained relative to OHT across all ages, assuming a median wait-list time of 5.6 months.
Among OHT-ineligible patients, DT-LVAD exceeds $150 000 per QALY gained relative to IDMT even for patients in their 40s. Some debate exists about whether DT-LVAD LVAD indicates left ventricular assist device; and QALY, quality-adjusted life-year. *Lifetime costs and QALYs are discounted at a 3% annual rate. †Results are based on a simulation of 20 000 hypothetical patients aged 50 years. ‡Incremental cost-effectiveness ratios for LVAD destination therapy and heart transplant are relative to inotrope-dependent medical therapy, and LVAD bridge to transplant is relative to heart transplant. should be offered to patients aged >70 years. 7, 15 In this analysis, DT-LVAD confers an average life expectancy of 3.6 years among patients aged >70 years (compared with 4.4 years for 50-year-old patients) with an ICER of $225 000 per QALY gained relative to OHT.
Transplant Wait Time
Median wait time for heart transplant is 5.6 months, with significant variability depending on region and patient characteristics including blood type, size, and allo-antibody sensitization. To assess the sensitivity of transplant wait-list time, we varied the median wait time from 0 to 24 months (Figure 4) . A projected life expectancy of 13.8 years conferred by immediate OHT decreases to 4.3 years given a median wait-list time of 24 months. The cost-effectiveness of OHT remains relatively constant because both life expectancy and lifetime costs decrease proportionately with longer waits. If the expected wait for OHT is <1 month, IDMT is preferred to BTT-LVAD while awaiting OHT. For any wait >1 month, BTT-LVAD generates the longest life expectancy. The cost-effectiveness of BTT-LVAD (relative to OHT only) improves as the wait-list time increases because the comparator strategy of IDMT followed by OHT worsens. For example, with a median transplant wait-list time of 24 months, BTT-LVAD costs $150 000 per QALY gained.
Medical Therapy Mortality
We examined how varying survival of patients on IDMT might influence health outcomes (Figure 4) . In our base-case analysis, the monthly probability of death for OHT-eligible IDMT patients was 0.074. Decreasing this probability by half increases the life expectancy with OHT from 8.5 to 10.8 years.
As one might expect, the cost-effectiveness of OHT or LVAD implantation worsens as IDMT survival improves, because the baseline strategy of IDMT seems more favorable. With an average life expectancy on IDMT of 2.5 years-sufficient time for most patients to receive OHT-the ICER for BTT-LVAD exceeded $500 000 per QALY gained.
Complication Rates
Our state-transition model incorporated clinically relevant postprocedural complications for the life of the patient. Hypothetically, if LVAD-specific and OHT-specific complications were eliminated completely, cost-effectiveness would improve substantially. OHT in patients with a 5.6-month median wait-list time would cost only $56 000 per QALY gained, BTT-LVAD would cost $128 000 per QALY gained, and DT-LVAD would cost ≈$100 000 per QALY gained. This suggests that that future improvements in LVAD implantation and management of complications could make DT-LVAD a viable alternative to heart transplantation.
Discussion
Our analysis adds to the growing body of evidence comparing clinical outcomes and costs of treatment for end-stage heart failure. Our projected survival rates and freedom from complications closely match values reported by INTERMACS for LVADs through 4 years postimplantation and by ISHLT for heart transplants through 7 years postsurgery. Because many clinical trials and observational studies track patients for a limited time, a comprehensive model such as the one we have developed can offer insights about long-term survival and health benefits of different therapies.
Our results suggest that OHT significantly improves life expectancy and costs <$100 000 per QALY gained, a threshold often considered cost effective for the United States. 43 Although the wait-list time influences survival and lifetime costs, OHT remains more cost effective than DT-LVAD in transplant-eligible patients, across a wide range of assumptions. We recognize, however, that certain OHT-eligible patients may experience precipitous decline in clinical condition and may require BTT-LVAD. Although this strategy does not meet conventional cost-effectiveness thresholds under our base-case assumptions, it offers a substantial gain in life expectancy compared with IDMT while awaiting OHT. With a longer transplant wait-list time, decreased index hospitalization costs, or reduced LVAD complication rates, the cost-effectiveness of BTT-LVAD falls <$150 000 per QALY gained.
The impact of DT-LVAD as a life-prolonging modality in critically ill patients who have no other option should be emphasized. The cost-effectiveness of this therapy has improved dramatically since a 2004 analysis based on the REMATCH trial data reported an ICER of $802 700. 45 We expect that as survival and quality of life continue to improve and as adverse events, lengths of stay, device costs, and need for readmission decrease, that cost-effectiveness of this strategy will continue to improve. Although a patient's age impacts overall life expectancy with an LVAD or OHT, increasing age alone does not impact the relative ranking of each strategy in terms of cost-effectiveness.
One challenge in studying a population with end-stage heart failure is its inherent heterogeneity. Prior studies have demonstrated that cost-effectiveness is not an inherent property of any particular therapy but depends on the patient population in which the therapy is used. 46 Accordingly, it is important to identify subgroups that will derive benefit based on appropriate, evidence-based selection of patients. To obtain appropriate survival estimates, we separated patients with stage D heart failure based on transplant eligibility. Patients who were OHT ineligible could only receive DT-LVAD as clinical guidelines dictate. In contrast, survival estimates for OHT-eligible patients were in accordance with status 1A or 1B patients who did not receive an LVAD. 45 These are clearly different subgroups with projected life expectancies that differ by 30% to 50%. In addition, OHT-eligible patients may need to move to DT-LVAD as occasionally occurs in clinical practice. The cost-effectiveness of LVAD as DT or BTT may worsen as survival on medical therapy alone improves.
Our cost-effectiveness estimates of DT-LVAD differ slightly from those reported by Rogers et al, 7 in part because we accounted for the decrement in utility from complications, stratified patients based on OHT-eligibility, and applied more recent INTERMACS data in which LVAD survival is improved. We found LVAD as BTT to be more cost effective than reported by Moreno et al 28 primarily because we assumed a lower survival rate in OHT-eligible IDMT patients by excluding from the analysis IDMT patients who subsequently underwent LVAD implantation.
Our analysis builds on prior studies through our inclusion of commonly tracked medical complications after LVAD implantation and OHT and their associated costs. If such costs were ignored, the cost-effectiveness of both strategies improved by ≈40%, highlighting the importance of including medical complications when evaluating relative cost-effectiveness. It also suggests that as the field continues to mature and outcomes improve, that cost-effectiveness should also improve.
A limitation of our study stems from the paucity of cost data associated with different health states in our model. Although our cost assumptions were based on published estimates, the exact patient population may differ, resulting in over-or underestimates. We estimated quality-of-life factors for each complication state based on published estimates that may include other patient populations. Future studies should examine the costs and utilities associated with each complication state. Mortality rates were extrapolated beyond available registry data for LVAD and transplant patients, which could be revised as additional data become available. Finally, our state-transition model included the most common tracked complications associated with LVADs or OHT, but the model simplified the complex progression of stage D heart failure.
In conclusion, our study demonstrates that heart transplantation results in improved survival and is a cost-effective strategy for most transplant-eligible patients with inotrope-dependent stage D heart failure, compared with medical therapy alone. However, if the anticipated wait-list time exceeds 1 month, BTT-LVAD results in greater life expectancy for patients awaiting OHT than medical therapy alone.
Given national average transplant wait times for status 1A and 1B patients, the cost-effectiveness of BTT-LVAD exceeds $225 000 per QALY gained, but improves substantially with longer expected transplant wait times. In patients ineligible for transplantation, DT-LVAD substantially improves survival compared with medical therapy, although advances in medical complication rates or implantation costs must improve to render it as cost effective as other medical technologies.
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